Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent - A phase II study of the EORTC early clinical trials group

Uta Bruntsch, Pierre Dodion, Wim W. Ten Bokkel Huinink, Heine H. Hansen, Herbert M. Pinedo, Mogens Hansen, Josette Renard, Martine Van Glabbeke

Research output: Contribution to journalArticle

Abstract

Fourteen patients with metastatic renal adenocarcinoma without prior chemotherapy were treated with 1,2,4-triglycidylurazol (TGU, NSC-332488), a new triepoxide alkylating agent. TGU was chosen for this study among other triepoxides because of its high antitumour activity in animal models, its relatively good water solubility and the expected favourable therapeutic index. The starting dose was 800 mg/m2 i.v. (600 mg/m2 for patients with prior extensive radiotherapy) every 4 weeks. No objective tumour regression was seen in this favourable group of patients. Leuko- and thrombocytopenia were the most important side-effects. Severe cumulative and prolonged thrombocytopenia was seen. Other toxicities observed were nausea with or without vomiting in all patients and local phlebitis in some.

Original languageEnglish (US)
Pages (from-to)697-699
Number of pages3
JournalEuropean Journal of Cancer and Clinical Oncology
Volume22
Issue number6
DOIs
StatePublished - 1986
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent - A phase II study of the EORTC early clinical trials group'. Together they form a unique fingerprint.

  • Cite this